School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
    • Contact Us
  • Education
    • Degree and Certificate Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory

Directory section navigation

  • Faculty Profiles

Emory University School of Medicine

  • About
    • Sub link
      Our Vision
    • Sub link
      Academic Departments
    • Sub link
      Our Leadership
    • Sub link
      Health Care Partnerships
    • Sub link
      Diversity, Equity, & Inclusion
    • Sub link
      Location
    • Sub link
      Supporting Our People
    • Sub link
      Our Faculty
    • Sub link
      History
    • Sub link
      News
    • Sub link
      Events
    • Sub link
      Contact Us
  • Education
    • Sub link
      Degree and Certificate Programs
    • Sub link
      Academic Departments
    • Sub link
      Residents & Fellows
    • Sub link
      Postdoctoral Training
    • Sub link
      Continuing Medical Education
    • Sub link
      Admissions
    • Sub link
      Cost and Financial Aid
    • Sub link
      Student Resources
  • Research
    • Sub link
      Research Innovation
    • Sub link
      Conducting Research
    • Sub link
      Core Facilities
    • Sub link
      Research Centers
    • Sub link
      Research Training
    • Sub link
      Academic Departments
    • Sub link
      Find a Researcher
    • Sub link
      Research News
  • Clinical Experience
    • Sub link
      Where We Work
    • Sub link
      Caring for a Diverse Population
    • Sub link
      Faculty Clinical Experience
    • Sub link
      Advanced Patient Care
    • Sub link
      Academic Departments
    • Sub link
      Community Learning
  • Giving
  • Directory
  • Home School of Medicine Home
  • Directory

Profile

Leonard Heffner Jr. MD

  • Department of Hematology and Medical Oncology
    Professor Emeritus
  • (404) 778-5871
  • lheffne@emory.edu
Head shot of Leonard Heffner Jr.

Academic Appointment

  • Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine

Education

Degrees

  • MD from Wake Forest University, Winston-Salem
  • BS from Davidson College

Research

Focus

  • Multiple myeloma, lymphoma, leukemia, Waldenstrms

Publications

  • Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenstrm's macroglobulinemia.
    Future Oncol Volume: 19 Page(s): 345 - 353
    02/01/2023 Authors: Buske C; Tedeschi A; Trotman J; Garca-Sanz R; MacDonald D; Leblond V; Mahe B; Herbaux C; Matous JV; Tam CS
  • Venetoclax ex vivo functional profiling predicts improved progression-free survival.
    Blood Cancer J Volume: 12 Page(s): 115
    08/04/2022 Authors: Gupta VA; Matulis SM; Barwick BG; Bog RD; Shebelut CW; Shanmugam M; Neri P; Bahlis NJ; Dhodapkar MV; Heffner LT
  • Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life.
    Transplant Cell Ther Volume: 28 Page(s): 75.e1 - 75.e7
    02/01/2022 Authors: Joseph NS; Gupta VA; Wyman S; Graiser M; Kaufman JL; Almaula D; Andrews J; Hofmeister C; Dhodapkar M; Heffner LT
  • Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrm's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
    J Clin Oncol Volume: 40 Page(s): 52 - 62
    01/01/2022 Authors: Buske C; Tedeschi A; Trotman J; Garca-Sanz R; MacDonald D; Leblond V; Mahe B; Herbaux C; Matous JV; Tam CS
  • Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.
    Blood Cancer Discov Volume: 2 Page(s): 600 - 615
    11/01/2021 Authors: Kaushal A; Nooka AK; Carr AR; Pendleton KE; Barwick BG; Manalo J; McCachren SS; Gupta VA; Joseph NS; Hofmeister CC
  • Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
    Lancet Haematol Volume: 8 Page(s): e794 - e807
    11/01/2021 Authors: Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A
  • Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression.
    Blood Volume: 137 Page(s): 3604 - 3615
    07/01/2021 Authors: Gupta VA; Barwick BG; Matulis SM; Shirasaki R; Jaye DL; Keats JJ; Oberlton B; Joseph NS; Hofmeister CC; Heffner LT
  • Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Blood Volume: 137 Page(s): 2634 - 2645
    05/13/2021 Authors: Hamadani M; Radford J; Carlo-Stella C; Caimi PF; Reid E; O'Connor OA; Feingold JM; Ardeshna KM; Townsend W; Solh M
  • Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia.
    JCO Oncol Pract Volume: 17 Page(s): e497 - e505
    04/01/2021 Authors: Jillella AP; Arellano ML; Gaddh M; Langston AA; Heffner LT; Winton EF; McLemore ML; Zhang C; Caprara CR; Simon KS
  • Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.
    Am J Hematol Volume: 96 Page(s): E68 - E71
    03/01/2021 Authors: Maples KT; Nooka AK; Gupta V; Joseph NS; Heffner LT; Hofmeister C; Dhodapkar M; Matulis SM; Lonial S; Boise LH
  • Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
    Clin Lymphoma Myeloma Leuk Volume: 20 Page(s): 797 - 803
    12/01/2020 Authors: Kaufman JL; Mina R; Shah JJ; Laubach JP; Nooka AK; Lewis C; Gleason C; Sharp C; Harvey RD; Heffner LT
  • Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
    J Clin Oncol Volume: 38 Page(s): 1928 - 1937
    06/10/2020 Authors: Joseph NS; Kaufman JL; Dhodapkar MV; Hofmeister CC; Almaula DK; Heffner LT; Gupta VA; Boise LH; Lonial S; Nooka AK
  • Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors.
    J Clin Med Volume: 9
    05/20/2020 Authors: Kong JH; Winton EF; Heffner LT; Gaddh M; Hill B; Neely J; Hatcher A; Joseph M; Arellano M; El-Rassi F
  • Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study.
    Cancer Volume: 126 Page(s): 1235 - 1242
    03/15/2020 Authors: Cohen JB; Wei L; Maddocks KJ; Christian B; Heffner LT; Langston AA; Lechowicz MJ; Porcu P; Flowers CR; Devine SM
  • Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.
    Blood Adv Volume: 4 Page(s): 449 - 457
    02/11/2020 Authors: Jain N; Stock W; Zeidan A; Atallah E; McCloskey J; Heffner L; Tomlinson B; Bhatnagar B; Feingold J; Ungar D
  • Daratumumab-associated hemophagocytic lymphohistiocytosis.
    Ann Hematol Volume: 99 Page(s): 181 - 182
    01/01/2020 Authors: Woods A; Wooten M; Thompson Heffner L; Waller E
  • A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
    Clin Cancer Res Volume: 25 Page(s): 6986 - 6994
    12/01/2019 Authors: Kahl BS; Hamadani M; Radford J; Carlo-Stella C; Caimi P; Reid E; Feingold JM; Ardeshna KM; Solh M; Heffner LT
  • ERRATUM: Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation.
    Hematol Rep Volume: 11 Page(s): 8395
    11/29/2019 Authors: Jillella AP; Arellano ML; Heffner LT; Gaddh M; Langston AA; Khoury HJ; Mangaonkar A; Kota VK
  • Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
    Blood Cancer J Volume: 9 Page(s): 94
    11/25/2019 Authors: Schmidt TM; Barwick BG; Joseph N; Heffner LT; Hofmeister CC; Bernal L; Dhodapkar MV; Gupta VA; Jaye DL; Wu J
  • Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.
    Haematologica Volume: 104 Page(s): 2258 - 2264
    11/01/2019 Authors: Mato AR; Wierda WG; Davids MS; Cheson BD; Coutre SE; Choi M; Furman RR; Heffner L; Barr PM; Eradat H
  • Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Blood Adv Volume: 3 Page(s): 3033 - 3037
    10/22/2019 Authors: Gkbuget N; Kantarjian HM; Brggemann M; Stein AS; Bargou RC; Dombret H; Fielding AK; Heffner L; Rigal-Huguet F; Litzow M
  • Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Volume: 125 Page(s): 2991 - 3000
    09/01/2019 Authors: Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
  • Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200.
    J Immunother Cancer Volume: 7 Page(s): 227
    08/23/2019 Authors: Mahadevan D; Lanasa MC; Farber C; Pandey M; Whelden M; Faas SJ; Ulery T; Kukreja A; Li L; Bedrosian CL
  • Daratumumab in multiple myeloma.
    Cancer Volume: 125 Page(s): 2364 - 2382
    07/15/2019 Authors: Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
  • Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.
    Br J Haematol Volume: 185 Page(s): 961 - 966
    06/01/2019 Authors: Wierda WG; Byrd JC; Davids MS; Furman RR; Cheson BD; Barr PM; Eradat H; Heffner L; Zhou L; Verdugo M
  • Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.
    Clin Lymphoma Myeloma Leuk Volume: 19 Page(s): 372 - 380
    06/01/2019 Authors: Jagannath S; Heffner LT; Ailawadhi S; Munshi NC; Zimmerman TM; Rosenblatt J; Lonial S; Chanan-Khan A; Ruehle M; Rharbaoui F
  • Acute Myeloid Leukemia in Young Adults: Does Everyone Need a Transplant?
    J Oncol Pract Volume: 15 Page(s): 315 - 320
    06/01/2019 Authors: Roberts MMSc D; Langston AA; Heffner LT
  • Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.
    Leukemia Volume: 33 Page(s): 1291 - 1296
    05/01/2019 Authors: Matulis SM; Gupta VA; Neri P; Bahlis NJ; Maciag P; Leverson JD; Heffner LT; Lonial S; Nooka AK; Kaufman JL
  • Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
    Cancer Volume: 125 Page(s): 416 - 423
    02/01/2019 Authors: Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK
  • Safety and survival outcomes for bloodless transplantation in patients with myeloma.
    Cancer Volume: 125 Page(s): 185 - 193
    01/15/2019 Authors: Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR
  • Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.
    Blood Cancer J Volume: 9 Page(s): 3
    01/04/2019 Authors: Kaufman JL; Mina R; Jakubowiak AJ; Zimmerman TL; Wolf JJ; Lewis C; Gleason C; Sharp C; Martin T; Heffner LT
  • Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Volume: 132
    11/29/2018 Authors: Radford J; Kahl BS; Hamadani M; Carlo-Stella C; Caimi P; Ardeshna KM; Feingold J; He S; Reid E; Solh M
  • TREATMENT OF VENOUS THROMBOEMBOLISM DURING INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE LEUKEMIA: A SINGLE CENTER EXPERIENCE
    Volume: 93 Page(s): E51 - E51
    09/01/2018 Authors: Patel B; Cheng E; McLemore M; Arellano M; Heffner LT; Winton EF; Bodo I; Langston A; Kota V; Gaddh M
  • Impact of obesity on response in 751 myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVd) induction.
    Volume: 36
    05/20/2018 Authors: Harvey RD; Kaufman JL; Heffner LT; Hofmeister CC; Dhodapkar MV; Lonial S; Nooka AK
  • Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
    Blood Volume: 131 Page(s): 1704 - 1711
    04/12/2018 Authors: Coutre S; Choi M; Furman RR; Eradat H; Heffner L; Jones JA; Chyla B; Zhou L; Agarwal S; Waskiewicz T
  • Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia.
    Leukemia Volume: 32 Page(s): 562 - 565
    02/01/2018 Authors: Topp MS; Stelljes M; Zugmaier G; Barnette P; Heffner LT; Trippett T; Duell J; Bargou RC; Holland C; Benjamin JE
  • Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One B-Cell Receptor Pathway Inhibitor (BCRi)
    Volume: 130
    12/07/2017 Authors: Wierda WG; Davids MS; Furman RR; Cheson BD; Barr PM; Eradat H; Heffner L; Jones J; Zhou L; Verdugo M
  • Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy
    Volume: 130
    12/07/2017 Authors: Mato AR; Wierda WG; Davids MS; Cheson BD; Coutre S; Choi M; Furman RR; Heffner L; Barr PM; Eradat H
  • Outcomes of Chronic Phase Chronic Myeloid Leukemia (CP-CML) after Sequential Treatment with Tyrosine Kinase Inhibitors (TKI)
    Volume: 130
    12/07/2017 Authors: Kong JH; Winton EF; Heffner L; Gaddh M; Hill B; Arellano ML; El-Rassi F; Kim A; Kota V
  • Outcomes after Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Phase Chronic Myeloid Leukemia
    Volume: 130
    12/07/2017 Authors: Kong JH; Winton EF; Heffner L; Gaddh M; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK
  • Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)
    Volume: 130
    12/07/2017 Authors: Joseph N; Almaula D; Gleason C; Heffner L; Boise LH; Kaufman JL; Lonial S; Nooka A
  • Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib.
    Clin Lymphoma Myeloma Leuk Volume: 17 Page(s): e71 - e73
    12/01/2017 Authors: Kota VK; Kong JH; Arellano M; El Rassi F; Gaddh M; Heffner LT; Winton EF; Jillella AP; McLemore ML; Khoury HJ
  • Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation.
    Hematol Rep Volume: 9 Page(s): 7083
    09/26/2017 Authors: Jillella AP; Arellano ML; Heffner LT; Gaddh M; Langston AA; Khoury HJ; Mangoankar A; Kota VK
  • Single-agent Ibrutinib is efficacious and well tolerated in Rituximab-refractory patients with Waldenstrom's Macroglobulinemia (WM): Initial results from an international, multicenter, open-label phase 3 substudy (iNNOVATE (TM))
    Volume: 40 Page(s): 119 - 119
    09/01/2017 Authors: Buske C; Trotman J; Tedeschi A; Matous J; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT
  • Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Cancer Volume: 123 Page(s): 2482 - 2488
    07/01/2017 Authors: Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A
  • PATIENT-REPORTED OUTCOMES (PROS) WITH IBRUTINIB: SUBSTUDY OF INNOVATETM FOR WALDENSTROM MACROGLOBULINEMIA (WM)
    Volume: 102 Page(s): 510 - 510
    06/26/2017 Authors: Trotman J; Dimopoulos MA; Tedeschi A; Matous JV; Heffner LT; Shustik C; Garcia-Sanz R; Castillo JJ; Leblond V; Kastritis E
  • Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).
    Clin Cancer Res Volume: 23 Page(s): 2400 - 2404
    05/15/2017 Authors: Treon SP; Meid K; Tripsas C; Heffner LT; Eradat H; Badros AZ; Xu L; Hunter ZR; Yang G; Patterson CJ
  • Ibrutinib for patients with rituximab-refractory Waldenstrm's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
    Lancet Oncol Volume: 18 Page(s): 241 - 250
    02/01/2017 Authors: Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT
  • a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)
    Volume: 128
    12/02/2016 Authors: Maddocks KJ; Cohen JB; Huang Y; Christian BA; Benson DM; Jones J; Flowers C; Heffner LT; Jenkins C; Sexton J
  • Outcomes of Chronic Phase Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitors Dose-Reductions
    Volume: 128
    12/02/2016 Authors: Kong JH; Khoury HJ; Winton EF; Heffner LT; Gaddh M; Arellano M; El-Rassi F; Kim AS; Jillella A; Bodo I
  • Single-agent Ibrutinib is efficacious and well tolerated in Rituximab-refractory patients with Waldenstrom's Macroglobulinemia (WM): Initial results from an international, multicenter, open-label phase 3 substudy (INNOVATE (TM))
    Volume: 39 Page(s): 119 - 119
    10/01/2016 Authors: Buske C; Trotman J; Tedeschi A; Matous J; Macdonald D; Tam C; Toumilhac O; Ma S; Oriol A; Heffner LT
  • DECREASING EARLY DEATHS IN ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN AN ACADEMIC CENTER IN THE US BY USING A SIMPLIFIED TREATMENT ALGORITHM AND DEDICATED APL EXPERTS
    Volume: 101 Page(s): 675 - 676
    06/01/2016 Authors: Jillella A; Mody M; Harpaul G; Arellano M; Khoury H; Al-Kadhimi Z; McLemore M; Winton E; Gaddh M; Heffner L
  • SINGLE-AGENT IBRUTINIB IN RITUXIMAB-REFRACTORY PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA (WM): UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL PHASE 3 SUBSTUDY (INNOVATETM)
    Volume: 101 Page(s): 256 - 257
    06/01/2016 Authors: Dimopoulos M; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner L
  • VENETOCLAX IS ACTIVE IN CLL PATIENTS WHO HAVE RELAPSED AFTER OR ARE REFRACTORY TO IBRUTINIB OR IDELALISIB
    Volume: 101 Page(s): 231 - 232
    06/01/2016 Authors: Coutre S; Wierda W; Choi M; Davids MS; Cheson BD; Furman RR; Lamanna N; Barr PM; Eradat H; Halwani A
  • Costs associated with induction chemotherapy in adult acute myeloid leukemia (AML) managed in a tertiary care specialized unit.
    Volume: 34
    05/20/2016 Authors: Gleason S; Howard DH; Liu Y; Goldstein DA; Arellano ML; Jillella AP; Gaddh M; Kota V; Winton EF; Heffner LT
  • A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (B-NHL).
    Volume: 34
    05/20/2016 Authors: Chung KY; Hamadani M; Kahl BS; Heffner LT; Caimi PF; Feingold JM; O'Connor OA
  • Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib.
    Volume: 34
    05/20/2016 Authors: Jones JA; Wierda WG; Choi MY; Davids MS; Cheson BD; Furman RR; Lamanna N; Barr PM; Eradat HA; Halwani AS
  • Efficacy and safety of single-agent ibrutinib in rituximab-refractory patients with Waldenstrom's macroglobulinemia (WM): Initial results from an international, multicenter, open-label phase 3 substudy (iNNOVATE (TM))
    Volume: 173 Page(s): 82 - 82
    04/01/2016 Authors: Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT
  • Early Allogeneic Stem Cell Transplantation Appears to Improve Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) Patients: A Multi-Institutional Review
    Volume: 22 Page(s): S202 - S202
    03/01/2016 Authors: Hathaway AR; Peker D; Jackson BE; Kota VK; Shah BD; Zhang L; Jillella AP; Arellano M; Heffner LT; Erba HP
  • Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia
    Volume: 126
    12/03/2015 Authors: Thomas SK; Harb WA; Beck JT; Nashat G; Palomba ML; Ansell SM; Eradat H; Libby EN; Advani RH; Hajdenberg J
  • A Phase I Study of Gemcitabine and Bendamustine in Relapsed/Refractory Hodgkin Lymphoma
    Volume: 126
    12/03/2015 Authors: Cohen JB; Wei L; Maddocks KJ; Heffner LT; Langston A; Flowers C; Devine SM; Blum KA
  • Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenstrom's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE (TM))
    Volume: 126
    12/03/2015 Authors: Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT
  • Early Allogeneic Stem Cell Transplantation and Use of Asparaginase during Induction Chemotherapy Appear to Improve Otherwise Poor Outcomes in Adult T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) Patients: A Multi Institutional Review
    Volume: 126
    12/03/2015 Authors: Borate U; Hathaway AR; Peker D; Jackson BE; Kota VK; Shah BD; Zhang L; Jillella A; Arellano M; Heffner LT
  • Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Single US Center Experience
    Volume: 126
    12/03/2015 Authors: Khoury HJ; Heffner LT; Arellano M; Jillella AP; Kota VK; Winton EF
  • Survival of Patients Diagnosed with Primary Refractory and Relapsed Acute Myeloid Leukemia from 2008-2012: A Single Institution Experience
    Volume: 126
    12/03/2015 Authors: Zeichner SB; Gleason S; Antun AG; Langston A; Heffner LT; Kota VK; Gaddh M; Arellano M
  • Decreasing Early Deaths in Acute Promyelocytic Leukemia (APL) By Using a Simplified Treatment Algorithm and Establishing a Network with Academic and Community Centers in USA
    Volume: 126
    12/03/2015 Authors: Jillella A; Arellano M; Bashey A; Vidito SI; Stuart RK; Leung C; Sitchenko K; Gaddh M; Heffner LT; Kolhe RB
  • A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
    Volume: 171 Page(s): 539 - 546
    11/01/2015 Authors: Cohen JB; Switchenko JM; Koff JL; Sinha R; Kaufman JL; Khoury HJ; Bumpers N; Colbert A; Hutchison-Rzepka A; Nastoupil LJ
  • Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 15 Page(s): 514 - 518
    09/01/2015 Authors: Cohen JB; Bucur S; Winton EF; Sinha R; Heffner LT; King N; Lonial S; Langston AA; Waller EK; Hutchison-Rzepka A
  • INFLUENCE OF BASELINE FACTORS ON OUTCOMES IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL) TREATED WITH BLINATUMOMAB
    Volume: 100 Page(s): 30 - 30
    06/01/2015 Authors: Topp MS; Goekbuget N; O'Brien S; Stein A; Jia C; Forman SJ; Bargou R; Fielding AK; Heffner LT; Larson RA
  • RETREATMENT WITH BLINATUMOMAB AFTER CD19-POSITIVE RELAPSE: EXPERIENCE FROM 3 TRIALS IN PATIENTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL)
    Volume: 100 Page(s): 31 - 32
    06/01/2015 Authors: Topp MS; Stelljes M; Zugmaier G; Barnette P; Heffner LT; Trippett T; Bargou R; Jia C; Benjamin J; Litzow MR
  • Factors influencing outcomes in patients (Pts) with relapsed/refractory b-precursor acute lymphoblastic leukemia (r/r ALL) treated with blinatumomab in a phase 2 study.
    Volume: 33
    05/20/2015 Authors: Kantarjian H; Goekbuget N; O'Brien SM; Stein AS; Jia C; Forman SJ; Bargou RC; Fielding AK; Heffner LT; Larson RA
  • Re-exposure to blinatumomab after CD19-positive relapse: Experience from three trials in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R ALL).
    Volume: 33
    05/20/2015 Authors: Topp MS; Stelljes M; Zugmaier G; Barnette P; Heffner LT; Trippett TM; Bargou RC; Holland C; Benjamin J; Litzow MR
  • A randomized, double-blind, placebo-controlled, phase 3 study of rituximab with or without ibrutinib for Waldenstrom's macroglobulinemia (PCYC-1127-CA).
    Volume: 33
    05/20/2015 Authors: Dimopoulos MA; Leleu X; Matous J; MacDonald D; Trotman J; Oriol A; Shustik C; Tedeschi A; Garcia-Sanz R; Heffner LT
  • A phase I study of gemcitabine and bendamustine in relapsed/refractory Hodgkin's lymphoma
    Volume: 33
    05/20/2015 Authors: Cohen JB; Wei L; Maddocks KJ; Heffner LT; Langston AA; Flowers C; Devine SM; Blum KA
  • Bloodless transplants for multiple myeloma are feasible and yield similar results as matched controls.
    Volume: 33
    05/20/2015 Authors: Obidike CO; Nooka AK; Kaufman JL; Heffner LT; Langston AA; Lonial S
  • Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.
    Volume: 121 Page(s): 853 - 862
    03/15/2015 Authors: Barbee MS; Nooka A; Kaufman JL; Kim S; Chen Z; Heffner LT; Lonial S; Harvey RD
  • Predictors of Survival Outcomes in Phase 1 Relapsed or Refractory Multiple Myeloma Patients
    CANCER Volume: 121 Page(s): 853 - 862
    03/15/2015 Authors: Barbee MS; Nooka A; Kaufman JL; Kim S; Chen Z; Heffner LT; Lonial S; Harvey RD
  • Predicting early blast transformation in chronic-phase chronic myeloid leukemia: is immunophenotyping the missing link?
    Cancer Volume: 121 Page(s): 872 - 875
    03/15/2015 Authors: El Rassi F; Bergsagel JD; Arellano M; Gaddh M; Jillella A; Kota V; Heffner LT; Winton EF; Khoury HJ
  • Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Lancet Oncol Volume: 16 Page(s): 57 - 66
    01/01/2015 Authors: Topp MS; Gkbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA
  • An Evaluation of Molecular Response in a Phase 2 Open-Label, Multicenter Confirmatory Study in Patients (pts) with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Receiving Treatment with the BiTE (R) Antibody Construct Blinatumomab
    BLOOD Volume: 124
    12/06/2014 Authors: Goekbuget N; Kantarjian H; Brueggemann M; Stein A; Bargou RC; Dombret H; Fielding AK; Heffner L; Rigal-Huguet F; Litzow M
  • Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib
    BLOOD Volume: 124
    12/06/2014 Authors: Kelly KR; Chanan-Khan A; Heffner LT; Somlo G; Siegel DS; Zimmerman T; Karnad A; Munshi NC; Jagannath S; Greenberg AL
  • Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
    BLOOD Volume: 124
    12/06/2014 Authors: Gleason C; Kaufman JL; Nooka AK; Valla K; Heffner LT; Bisht AS; Manubolu S; Watson M; Boise LH; Lonial S
  • Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial
    Volume: 124
    12/06/2014 Authors: Kaufman JL; Zimmerman T; Rosenbaum CA; Nooka AK; Heffner LT; Harvey RD; Gleason C; Lewis C; Sharp C; Barron KW
  • Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.
    Blood Volume: 124 Page(s): 2498 - 2506
    10/16/2014 Authors: Reece DE; Hegenbart U; Sanchorawala V; Merlini G; Palladini G; Blad J; Fermand J-P; Hassoun H; Heffner L; Kukreti V
  • Cardiac plasmacytoma: a rare clinical entity.
    Tex Heart Inst J Volume: 41 Page(s): 554 - 557
    10/01/2014 Authors: Vrettou A-R; Heffner LT; Rossi PJ; Clements SD
  • Early Blast Phase Transformation In Chronic Phase Chronic Myeloid Leukemia: Is Flow Cytometry The Missing Link?
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 14 Page(s): S136 - S137
    09/01/2014 Authors: El Rassi F; Arellano M; Winton E; Heffner L; Gaddh M; Khoury HJ
  • Incidence and geographic distribution of adult acute leukemia in the state of Georgia.
    South Med J Volume: 107 Page(s): 497 - 500
    08/01/2014 Authors: El Rassi F; Ward KC; Flowers CR; Heffner LT; Waller EK; Winton EF; Vaughn J; Hill BG; Langston A; Nooka A
  • Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma.
    Leuk Lymphoma Volume: 55 Page(s): 1498 - 1500
    07/01/2014 Authors: Mitri Z; Siddiqui MT; El Rassi F; Holden JT; Heffner LT; Langston A; Waller EK; Winton E; McLemore M; Bernal-Mizrachi L
  • Prepregnancy body mass index and risk of preterm birth: association heterogeneity by preterm subgroups.
    BMC Pregnancy Childbirth Volume: 14 Page(s): 153
    04/30/2014 Authors: Parker MG; Ouyang F; Pearson C; Gillman MW; Belfort MB; Hong X; Wang G; Heffner L; Zuckerman B; Wang X
  • Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.
    Leukemia Volume: 28 Page(s): 690 - 693
    03/01/2014 Authors: Nooka AK; Kaufman JL; Muppidi S; Langston A; Heffner LT; Gleason C; Casbourne D; Saxe D; Boise LH; Lonial S
  • Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 13 Page(s): 657 - 663
    12/01/2013 Authors: Sinha R; Shenoy PJ; King N; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman J; Heffner LT
  • Prospective, Multicenter Study Of The Mtor Inhibitor Everolimus (RADoo1) As Primary Therapy In Waldenstrom's Macroglobulinemia
    Volume: 122
    11/15/2013 Authors: Treon SP; Tripsas CK; Meid K; Patterson C; Heffner LT; Eradat H; Gregory SA; Thomas SK; Advani RH; Baz R
  • Using Serum Free Light Chain (SFLC) Ratio and Serum Protein Electrophoresis (SPEP) As a Substitute For 24-Hour Urine Studies In Myeloma Patients
    Volume: 122
    11/15/2013 Authors: Shah NN; Nooka AK; Harvey D; Kaufman JL; Langston A; Nickleach D; Gleason C; Heffner LT; Boise LH; Lonial S
  • Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies.
    Cancer Volume: 119 Page(s): 3784 - 3787
    11/01/2013 Authors: Antun AG; Gleason S; Arellano M; Langston AA; McLemore ML; Gaddh M; el Rassi F; Bernal-Mizrachi L; Galipeau J; Heffner LT
  • Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia.
    Clin Lymphoma Myeloma Leuk Volume: 13 Page(s): 430 - 434
    08/01/2013 Authors: Wetzler M; Thomas DA; Wang ES; Shepard R; Ford LA; Heffner TL; Parekh S; Andreeff M; O'Brien S; Kantarjian HM
  • Results after long-term follow-up from the CAN2007 phase I/II study of weekly or twice-weekly bortezomib in patients (pts) with relapsed systemic light-chain (AL) amyloidosis
    Volume: 31
    05/20/2013 Authors: Reece DE; Hegenbart U; Sanchorawala V; Merlini G; Palladini G; Blade J; Fermand J-P; Hassoun H; Heffner L; Pei L
  • Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM)
    Volume: 31
    05/20/2013 Authors: Nooka AK; Langston AA; Waller EK; Heffner LT; Gleason C; Muppidi S; Watson M; Casbourne D; Boise L; Kaufman JL
  • Treatment of adults with acute lymphoblastic leukemia: do the specifics of the regimen matter?: Results from a prospective randomized trial.
    Cancer Volume: 119 Page(s): 1186 - 1194
    03/15/2013 Authors: Lamanna N; Heffner LT; Kalaycio M; Schiller G; Coutre S; Moore J; Seiter K; Maslak P; Panageas K; Golde D
  • High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
    J Clin Oncol Volume: 31 Page(s): 676 - 683
    02/20/2013 Authors: O'Brien S; Schiller G; Lister J; Damon L; Goldberg S; Aulitzky W; Ben-Yehuda D; Stock W; Coutre S; Douer D
  • Incidence and Geographic Distribution of Adult Acute Lymphoblastic Leukemia in the State of Georgia
    Volume: 120
    11/16/2012 Authors: El Rassi F; Arellano M; Heffner LT; Waller EK; Winton EF; Ward K; Khoury HJ
  • Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia.
    Cancer Volume: 118 Page(s): 5278 - 5282
    11/01/2012 Authors: Arellano M; Pakkala S; Langston A; Tighiouart M; Pan L; Chen Z; Heffner LT; Lonial S; Winton E; Khoury HJ
  • Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase.
    Br J Haematol Volume: 158 Page(s): 608 - 614
    09/01/2012 Authors: Muringampurath-John D; Jaye DL; Flowers CR; Saxe D; Chen Z; Lechowicz MJ; Weisenburger DD; Bast M; Arellano ML; Bernal-Mizrachi L
  • A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
    Cancer Volume: 118 Page(s): 3538 - 3548
    07/15/2012 Authors: Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT
  • Survival outcomes of early autologous stem cell transplant (ASCT) followed by lenalidomide, bortezomib, and dexamethasone (RVD) maintenance in patients with high-risk multiple myeloma (MM).
    Volume: 30
    05/20/2012 Authors: Kaufman JL; Nooka AK; Muppidi S; Heffner LT; Gleason C; Boise L; Lonial S
  • Efscalefect of lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (MM) on CR rates and survival.
    Volume: 30
    05/20/2012 Authors: Gleason C; Nooka AK; Muppidi S; Heffner LT; Steuer CE; Kumar M; Casbourne D; Langston AA; Watson M; Boise L
  • Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma.
    Leuk Lymphoma Volume: 53 Page(s): 725 - 727
    04/01/2012 Authors: Muringampurath-John D; Flowers CR; Toscano M; Zhengjia C; Kaufman JL; Arellano M; Bernal-Mizrachi L; Heffner LT; Lechowicz M-J; McLemore M
  • Managing chronic myeloid leukemia: a coordinated team care perspective.
    Clin Lymphoma Myeloma Leuk Volume: 12 Page(s): 88 - 93
    04/01/2012 Authors: Holloway S; Lord K; Bethelmie-Bryan B; Shepard MW; Neely J; McLemore M; Reddy SK; Montero A; Jonas WS; Gladney SP
  • High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years.
    Cancer Volume: 118 Page(s): 428 - 433
    01/15/2012 Authors: Arellano M; Winton E; Pan L; Lima L; Tighiouart M; Bhalla K; Heffner LT; Neely J; Hutcherson D; McLemore M
  • Vinorelbine, Paclitaxel, Etoposide, Cisplatin and Cytarabine (VTEPA) Is An Effective Salvage Therapy for Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) but Not for R/R Diffuse Large B Cell Lymphoma (DLBCL)
    Volume: 118 Page(s): 707 - 708
    11/18/2011 Authors: Sinha R; King N; Shenoy PJ; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman JL; Heffner LT
  • Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia
    Volume: 118 Page(s): 1273 - 1274
    11/18/2011 Authors: Treon SP; Tripsas CK; Ioakimidis L; Warren D; Patterson C; Heffner L; Eradat H; Gregory SA; Thomas S; Advani R
  • Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.
    QJM Volume: 104 Page(s): 957 - 970
    11/01/2011 Authors: Dubrey SW; Reece DE; Sanchorawala V; Hegenbart U; Merlini G; Palladini G; Fermand J-P; Vescio RA; Blad J; Heffner LT
  • Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia.
    Clin Lymphoma Myeloma Leuk Volume: 11 Page(s): 427 - 432
    10/01/2011 Authors: Arellano M; Bernal-Mizrachi L; Pan L; Tighiouart M; Souza L; Guo X; McLemore M; Lima L; Sunay S; Heffner LT
  • Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.
    Blood Volume: 118 Page(s): 865 - 873
    07/28/2011 Authors: Reece DE; Hegenbart U; Sanchorawala V; Merlini G; Palladini G; Blad J; Fermand J-P; Hassoun H; Heffner L; Vescio RA
  • A new formulation of vincristine for acute lymphoblastic leukemia.
    Clin Adv Hematol Oncol Volume: 9 Page(s): 314 - 316
    04/01/2011 Authors: Heffner L
  • Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond.
    Cancer Volume: 117 Page(s): 1245 - 1252
    03/15/2011 Authors: Lima L; Bernal-Mizrachi L; Saxe D; Mann KP; Tighiouart M; Arellano M; Heffner L; McLemore M; Langston A; Winton E
  • Margibo (R) (vincristine sulfate liposomes injection; VSLI) In the Treatment of Adult Patients with Advanced, Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL): A Combined Analysis of the VSLI-06 and RALLY Studies.
    Volume: 116 Page(s): 885 - 885
    11/19/2010 Authors: O'Brien S; Thomas DA; Heffner LT; Stock W; Messerschmidt GL; Hagey A; Deitcher SR; Kantarjian H
  • BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
    Volume: 116 Page(s): 1262 - 1262
    11/19/2010 Authors: Jagannath S; Chanan-Khan AA; Heffner LT; Avigan D; Lutz RJ; Uherek C; Osterroth F; Ruehle M; Haeder T; Niemann G
  • Lenalidomide, Bortezomib, and Dexamethasone (RVD) In Combination with Vorinostat as Front-Line Therapy for Patients with Multiple Myeloma (MM): Initial Results of a Phase 1 Study.
    Volume: 116 Page(s): 1251 - 1251
    11/19/2010 Authors: Kaufman JL; Shah JJ; Laubach JP; Heffner L; Francis D; Harvey RD; Lewis C; Tighiouart M; Richardson P; Orlowski RZ
  • First-In-Human Phase I Dose Escalation Study of a Humanized Anti-CD200 Antibody (Samalizumab) In Patients with Advanced Stage B Cell Chronic Lymphocytic Leukemia (B-CLL) or Multiple Myeloma (MM)
    Volume: 116 Page(s): 1024 - 1024
    11/19/2010 Authors: Mahadevan D; Lanasa MC; Whelden M; Faas SJ; Ulery TL; Kukreja A; Li L; Bedrosian CL; Heffner LT
  • A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
    Clin Cancer Res Volume: 16 Page(s): 5079 - 5086
    10/15/2010 Authors: Lonial S; Kaufman J; Tighiouart M; Nooka A; Langston AA; Heffner LT; Torre C; McMillan S; Renfroe H; Harvey RD
  • Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters.
    Leuk Lymphoma Volume: 51 Page(s): 1473 - 1477
    08/01/2010 Authors: Tran H; Arellano M; Chamsuddin A; Flowers C; Heffner LT; Langston A; Lechowicz MJ; Tindol A; Waller E; Winton EF
  • Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Cancer Volume: 116 Page(s): 3143 - 3151
    07/01/2010 Authors: Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
  • Safety and efficacy of HiDAC induction in de novo AML patients age 60 and older.
    JOURNAL OF CLINICAL ONCOLOGY Volume: 28
    05/20/2010 Authors: Arellano ML; Pan L; Lima L; Tighiouart M; Heffner LT; Langston AA; McLemore M; Neely J; Winton EF; Khoury HJ
  • A PHASE I/II STUDY TARGETING THE IMMUNOSUPPRESSIVE MOLECULE CD200 IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) USING THE HUMANIZED ANTIBODY SAMALIZUMAB
    Volume: 21 Page(s): 43 - 43
    01/01/2010 Authors: Mahadevan D; Lanasa MC; Farber CM; Whelden M; Faas SJ; Ulery T; Kukreja A; Li L; Bedrosian CL; Heffner LT
  • Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
    Cancer Volume: 115 Page(s): 5490 - 5498
    12/01/2009 Authors: Thomas DA; Kantarjian HM; Stock W; Heffner LT; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Pierce S; Lu B
  • Clinical value of minor responses after 4 doses of rituximab in Waldenstrm macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.
    Br J Haematol Volume: 147 Page(s): 677 - 680
    12/01/2009 Authors: Gertz MA; Abonour R; Heffner LT; Greipp PR; Uno H; Rajkumar SV
  • Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.
    Volume: 114 Page(s): 738 - 739
    11/20/2009 Authors: Chanan-Khan AA; Jagannath S; Heffner LT; Avigan D; Lee KP; Lutz RJ; Haeder T; Ruehle M; Uherek C; Wartenberg-Demand AB
  • Thromboembolic Events (TEE) with Lenalidomide-Based Therapies for Multiple Myeloma (MM): Emory Experience.
    Volume: 114 Page(s): 1496 - 1496
    11/20/2009 Authors: Nooka AK; Kaufman JL; Heffner LT; Gleason CL; Lonial S
  • Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo (R)) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-leukemia Treatment Lines.
    Volume: 114 Page(s): 1200 - 1201
    11/20/2009 Authors: O'Brien S; Schiller G; Damon LE; Lister J; Ravandi F; Douer D; Masood A; Ben-Yehuda D; Rowe JM; Goekbuget N
  • Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
    J Clin Oncol Volume: 27 Page(s): 3518 - 3525
    07/20/2009 Authors: Richardson PG; Xie W; Mitsiades C; Chanan-Khan AA; Lonial S; Hassoun H; Avigan DE; Oaklander AL; Kuter DJ; Wen PY
  • Long-lasting responses after four doses of rituximab in Waldenstrom's macroglobulinemia: Clinical value of minor responses: A follow-up of the Eastern Cooperative Oncology Group E3A98 trial
    Volume: 27
    05/20/2009 Authors: Gertz MA; Abonour R; Heffner LT; Greipp PR; Uno H; Rajkumar SV
  • Monitoring chronic myeloid leukemia (CML) response to tyrosine kinase inhibitors (TKI) and homoharringtonine (HHT) using peripheral blood (PB) fluorescence in situ hybridization (FISH) and quantitative RT-PCR (Q-PCR): Are bone marrow biopsies still needed?
    Volume: 27
    05/20/2009 Authors: Khoury HJ; Lima L; Saxe D; Mann KP; Arellano M; Heffner L; Bernal-Mizrachi L; McLemore M; Langston A; Winton E
  • A phase II study of the tolerability and activity of weekly vincristine sulfate liposomes injection (VSLI) in adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second relapse or progressing following two antileukemia treatment lines
    Volume: 27
    05/20/2009 Authors: Heffner LT; Damon LE; Larson ML; Schiller G; Stock W; Kantarjian HM; Lu B; Imperiale SM; O'Brien S
  • Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia (AML)
    Volume: 27
    05/20/2009 Authors: Arellano ML; Winton E; Pan L; Souza L; Sunay S; Lima L; McLemore M; Heffner LT; Langston A; Khoury HJ
  • Long-lasting responses after four doses of rituximab in Waldenstrm's macroglobulinemia: Clinical value of minor responses: A follow-up of the Eastern Cooperative Oncology Group E3A98 trial.
    J Clin Oncol Volume: 27 Page(s): 8513
    05/20/2009 Authors: Gertz MA; Abonour R; Heffner LT; Greipp PR; Uno H; Rajkumar SV
  • Monitoring chronic myeloid leukemia (CML) response to tyrosine kinase inhibitors (TKI) and homoharringtonine (HHT) using peripheral blood (PB) fluorescence in situ hybridization (FISH) and quantitative RT-PCR (Q-PCR): Are bone marrow biopsies still needed?
    J Clin Oncol Volume: 27 Page(s): 7064
    05/20/2009 Authors: Khoury HJ; Lima L; Saxe D; Mann KP; Arellano M; Heffner L; Bernal-Mizrachi L; McLemore M; Langston A; Winton E
  • Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia (AML).
    J Clin Oncol Volume: 27 Page(s): 7070
    05/20/2009 Authors: Arellano ML; Winton E; Pan L; Souza L; Sunay S; Lima L; McLemore M; Heffner LT; Langston A; Khoury HJ
  • A phase II study of the tolerability and activity of weekly vincristine sulfate liposomes injection (VSLI) in adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second relapse or progressing following two antileukemia treatment lines.
    J Clin Oncol Volume: 27 Page(s): 7046
    05/20/2009 Authors: Heffner LT; Damon LE; Larson ML; Schiller G; Stock W; Kantarjian HM; Lu B; Imperiale SM; O'Brien S
  • A Randomized Phase I Study of Melphalan and Bortezomib for Autologous Transplant in Myeloma
    CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S60 - S60
    02/01/2009 Authors: Kaufman JL; Lonial S; Sinha R; Torre C; Langston AA; Lechowicz MJ; Flowers C; McMillan S; Renfroe H; Heffner LT
  • Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study
    Volume: 112 Page(s): 1247 - 1247
    11/16/2008 Authors: Langston AA; Murali S; McMillan S; Heffner LT; Lonial S; Waller EK; Flowers CR; Kaufman J; McLemore ML; Sinha R
  • A Randomized Phase I Trial of Melphalan plus Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration
    Volume: 112 Page(s): 1144 - 1145
    11/16/2008 Authors: Lonial S; Kaufman J; Torre C; Langston A; Lechowicz MJ; Flowers C; McMillan S; Renfroe H; Heffner LT; Waller EK
  • Phase 1 Study of Weekly Vincristine Sulfate (VCR) Liposomes Injection (VSLI, Marqibo (TM)) Plus Dexamethasone in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
    Volume: 112 Page(s): 1008 - 1008
    11/16/2008 Authors: Thomas DA; Kantarjian HM; Stock W; Heffner L; Hirabayashi S; Lu B; Deitcher SR; O'Brien S
  • Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma.
    Bone Marrow Transplant Volume: 42 Page(s): 529 - 534
    10/01/2008 Authors: Murali S; Winton E; Waller EK; Heffner LT; Lonial S; Flowers C; Kaufman J; Arellano M; Lechowicz MJ; Mann KP
  • Staging in Multiple Myeloma
    Page(s): 3 - 7
    01/01/2008 Authors: Heffner LT
  • A randomized phase I trial of Melphalan plus Bortezomib as conditioning for autologous transplant for myeloma: The effect of sequence of administration
    Volume: 110 Page(s): 288A - 289A
    11/16/2007 Authors: Lonial S; Kaufman J; Langston A; Heffner LT; Torre C; Lechowicz MJ; Flowers C; McMillan S; Arnold M; Waller NK
  • Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma
    Volume: 110 Page(s): 1055A - 1055A
    11/16/2007 Authors: Kaufman JL; Gleason C; Heffner L; Lonial S
  • Safety and efficacy of marqibo (vincristine sulfate liposomes injection, OPTISOME (TM)) in for the treatment of adults with relapsed or refractory acute lymphoblastic leukemia (ALL)
    Volume: 110 Page(s): 263A - 263A
    11/16/2007 Authors: Thomas DA; Kantarjian HM; Stock W; Heffner L; Tredinnick A; Lu B; Choy GS; Deitcher SR; O'Brien SM
  • Bortezomib,thalidomide and dexamethasone as induction
    Volume: 92 Page(s): 181 - 181
    06/01/2007 Authors: Kaufman JL; Gleason C; Heffner LT; Langston AA; Waller EK; Lonial S
  • Phase I trial of sphingosomal vincristine (SV, Marqibo (R)) and dexamethasone in relapsed or refractory acute lymphocytic leukemia (ALL).
    Volume: 108 Page(s): 214B - 214B
    11/16/2006 Authors: Thomas DA; Kantaijian HM; Heffner L; Stock W; Garcia-Manero G; Faderl S; Ferrajoli A; Giles F; Wierda W; Ravandi-Kashani F
  • Tolerability and anti-leukemic activity of ara-C, topotecan, and gemtuzumab ozogamicin [ATGO] in advanced MDS and AML: Interim analysis of phase I/II data.
    Volume: 108 Page(s): 554A - 554A
    11/16/2006 Authors: Murali S; Winton EF; McMillan S; Lonial S; Waller N; Heffner L; Flowers C; Kaufman JL; Lechowicz MJ; Khoury HJ
  • Deep venous thromboses associated with peripherally inserted central catheters in patients with hematological malignancies.
    Volume: 108 Page(s): 226B - 226B
    11/16/2006 Authors: Tran H; Chamsuddin A; Winton EF; Heffner L; Langston A; Waller N; Arellano M; Khoury HJ
  • Benefits of CHOP-14 followed by transplantation in patients with peripheral T-cell lymphoma.
    Volume: 108 Page(s): 254B - 254B
    11/16/2006 Authors: Abouyabis AN; Lechowicz M; Mann K; Heffner LT; Winton E; Bucur S; Flowers CR
  • Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
    Leuk Lymphoma Volume: 47 Page(s): 2155 - 2162
    10/01/2006 Authors: Lonial S; Arellano M; Hutcherson D; Langston A; Flowers C; Heffner LT; Winton E; Jo Lechowicz M; Waller EK
  • Single-agent bortezomib in previously untreated multiple myeloma (MM): Results of a phase II multicenter study.
    Volume: 24 Page(s): 423S - 423S
    06/20/2006 Authors: Anderson K; Richardson P; Chanan-Khan A; Schlossman R; Munshi N; Oaklander A; Heffner L; Hassoun H; Avigan D; Amato A
  • Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
    Cancer Volume: 106 Page(s): 2171 - 2180
    05/15/2006 Authors: Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
  • Multiple myeloma (MM) polyneuropathy before and after initial chemotherapy with single-agent bortezomib
    Volume: 60 Page(s): S94 - S94
    01/01/2006 Authors: Oaklander AL; Richardson PG; Briemberg H; Anderson KC; Wen P; Chan-Khan AA; Schlossman RL; Munshi NC; Heffner LT; Hassoun H
  • Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
    Blood Volume: 106 Page(s): 3777 - 3784
    12/01/2005 Authors: Lonial S; Waller EK; Richardson PG; Jagannath S; Orlowski RZ; Giver CR; Jaye DL; Francis D; Giusti S; Torre C
  • Relapse free survival of elderly AML patients is comparable to that of younger adults when treated with a modified dose intensive cytarabine regimen.
    Volume: 106 Page(s): 237B - 237B
    11/16/2005 Authors: Langston AA; Heffner LT; Hutcherson D; Neely J; Flowers C; Waller EK; Lonial S; Khoury HJ; Winton E
  • Prognostic significance of early peripheral blood blasts clearance following induction chemotherapy for adult acute myeloid leukemia.
    Volume: 106 Page(s): 236B - 236B
    11/16/2005 Authors: Pakkala S; Winton E; Langston A; Heffner LT; Khoury HJ
  • Patient characteristics in CD 20(+) and CD 20(-) adult acute lymphoblastic leukemia (ALL): A single institution analysis.
    Volume: 106 Page(s): 210B - 210B
    11/16/2005 Authors: Gladney SP; Heffner LT; Langston A; Holden J; Phillips C; Winton E; Flowers CR; Lechowicz MJ; Lonial S; Waller E
  • A randomized trial of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy for adult patients with ALL.
    Volume: 23 Page(s): 564S - 564S
    06/01/2005 Authors: Weiss MA; Heffner L; Lamanna N; Kalaycio M; Schiller G; Coutre S; Maslak P; Jurcic J; Panageas K; Scheinberg DA
  • Bortezomib-associated transient and cyclical thrombocytopenia: evidence for lack of marrow cytotoxicity.
    Volume: 23 Page(s): 587S - 587S
    06/01/2005 Authors: Lonial S; Waller EK; Richardson PG; Jagannath S; Orlowski RZ; Giver CR; Jaye DL; Barlogie B; Heffner LT; Anderson KC
  • A phase I trial of ara-C, topotecan, and gemtuzumab ozogamicin (Mylotarg (R)) for advanced MDS and secondary or relapsed AML.
    Volume: 104 Page(s): 502A - 502A
    11/16/2004 Authors: Langston AA; McMillan S; Lonial S; Smith K; Waller EK; Heffner LT; Bucur S; Redei I; Flowers C; Lechowicz MJ
  • Retrospective review of therapy with reduced dose rasburicase in adults with hyperuricemia associated with malignancy
    Volume: 10 Page(s): 104 - 104
    02/01/2004 Authors: Hutcherson DA; Sessions JK; Mihelic RA; Shayani S; Barreras AM; Bucur SZ; Heffner LT; Langston AA
  • Evaluation of the degree of thrombocytopenia and associated risk factors following bortezomib therapy for relapsed multiple myeloma.
    Volume: 102 Page(s): 447A - 447A
    11/16/2003 Authors: Lonial S; Waller EK; Richardson PG; Jagannath S; Francis D; Lehman M; Torre C; Barlogie B; Berenson JR; Singhal S
  • A phase I study of dose escalated cytarabine in combination with a modified ESHAP-like regimen, paclitaxel, and vinorelbine (VTEPA) for the treatment of relapsed/refractory lymphoma.
    Volume: 102 Page(s): 293B - 293B
    11/16/2003 Authors: Lonial S; Tanner A; Langston AA; Redei I; Heffner LT; Bucur SZ; Hutcherson D; Winton E; Waller EK
  • Early autologous transplantation for mantle cell lymphoma may improve long term disease-free survival.
    Volume: 102 Page(s): 734A - 735A
    11/16/2003 Authors: Murali S; Lonial S; Redei I; Smith K; Waller EK; Heffner LT; Bucur S; Winton E; Manion K; Langston A
  • A phase I trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg (R)) for advanced MDS and secondary or relapsed AML.
    Volume: 102 Page(s): 333B - 333B
    11/16/2003 Authors: Langston AA; Tanner A; Lonial S; Heffner LT; Smith K; Bucur S; Waller EK; Redei I; Winton E
  • Signal transduction and myeloma: new targets, new hope.
    Cancer Biol Ther Volume: 2 Page(s): 310 - 319
    01/01/2003 Authors: Lonial S; Waller EK; Simons JW; Heffner LT
  • Breakthroughs in the management of multiple myeloma.
    Drugs Volume: 63 Page(s): 1621 - 1636
    01/01/2003 Authors: Heffner LT; Lonial S
  • Therapy with thalidomide enhances overall survival after autologous PBSC transplant for multiple myeloma.
    Volume: 100 Page(s): 178A - 178A
    11/16/2002 Authors: Brinker B; Waller EK; Langston AA; Redei I; Smith KJ; Bucur SZ; Winton E; Lyles R; Heffner LT; Lonial S
  • CD34 selection of peripheral blood progenitor cells for autologous transplant in myeloma and amyloidosis is associated with an increased risk of post-transplant varicella Zoster.
    BLOOD Volume: 98 Page(s): 392A - 392A
    11/16/2001 Authors: Smith KJ; Hamilton ES; Waller EK; Langston AA; Redei I; Lonial S; Heffner LT
  • Non-fatal Veno-Occlusive disease in non-transplant patients after treatment of relapsed AML with Mylotarg (gemtuzumab ozogamicin).
    BLOOD Volume: 98 Page(s): 201B - 202B
    11/16/2001 Authors: Langston AA; Feinstein B; Hutcherson D; Heffner LT; Redei I; Smith K; Lonial S; Bucur S; Jones A; Waller EK
  • High dose chemotherapy without hematopoietic cell support for the treatment of refractory lymphoma.
    Leuk Lymphoma Volume: 36 Page(s): 497 - 502
    02/01/2000 Authors: Lonial S; Jones TW; Devine S; Winton EF; Heffner LT; Smith KJ; Yeager AM; Waller EK
  • Autologous peripheral blood stem cell (PBSC) transplantation in AML: Outcome and flow cytometric analysis of the PBSC product.
    BLOOD Volume: 94 Page(s): 398B - 398B
    11/15/1999 Authors: Bucur SZ; Heffner LT; Langston AA; Redei J; Waller EK; Winton EF; Holden JT; Smith KJ
  • Modified high dose Ara-C (mHiDAC) and daunorubicin as induction therapy for newly diagnosed AML without t(15;17).
    BLOOD Volume: 94 Page(s): 233B - 233B
    11/15/1999 Authors: Lonial S; Langston AA; Bhalla K; Smith KJ; Heffner LT; Bucur S; Hutcherson DA; Winton EF
  • Phase II study of PSC 833 (PSC) and vad chemotherapy in patients with VAD-refractory multiple myeloma (MM).
    BLOOD Volume: 92 Page(s): 105A - 105A
    11/15/1998 Authors: Case DC; Jain V; Stiff P; Jansen J; Stewart AK; Shurafa M; Hussein M; Heffner LT; Irwin D; Greipp P
  • Presence of minimal residual disease (MRD) in acute myelogenous leukemia (AML) patients preallogeneic bone marrow transplantation (BMT) is associated with a lower relapse-free survival (RFS).
    EXPERIMENTAL HEMATOLOGY Volume: 25 Page(s): 621 - 621
    08/01/1997 Authors: Holland HK; Bray RA; OToole K; Holden JT; Connaghan DG; Heffner LT; Waller EK; Winton EF; Yeager AM
  • Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation.
    Bone Marrow Transplant Volume: 20 Page(s): 219 - 225
    08/01/1997 Authors: Geller RB; Devine SM; O'Toole K; Persons L; Keller J; Mauer D; Holland HK; Dix SP; Piotti M; Redei I
  • The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Biol Blood Marrow Transplant Volume: 3 Page(s): 25 - 33
    04/01/1997 Authors: Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT
  • Long term follow-up of edelfosine purging for autologous bone marrow transplantation (ABMT) in acute leukemia.
    EXPERIMENTAL HEMATOLOGY Volume: 24 Page(s): 615 - 615
    08/01/1996 Authors: Vogler WR; Berdel WE; Winton EF; Gordon DS; Geller RB; Heffner LT; Brochstein JA; Beveridge RA; Dalton WS; Miller KB
  • Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.
    J Clin Oncol Volume: 14 Page(s): 1156 - 1164
    04/01/1996 Authors: Holland HK; Dix SP; Geller RB; Devine SM; Heffner LT; Connaghan DG; Hillyer CD; Hughes LL; Miller RL; Moore MR
  • Association of busulfan area under the curve with veno-occlusive disease following BMT.
    Bone Marrow Transplant Volume: 17 Page(s): 225 - 230
    02/01/1996 Authors: Dix SP; Wingard JR; Mullins RE; Jerkunica I; Davidson TG; Gilmore CE; York RC; Lin LS; Devine SM; Geller RB
  • High dose cyclophosphamide, fractionated total body irradiation with involved field irradiation and autologous bone marrow transplantation in malignant lymphoma.
    Leuk Lymphoma Volume: 20 Page(s): 249 - 257
    01/01/1996 Authors: Tirona MR; Gordon DS; Crocker I; Eley JW; York R; Heffner LT; Winton EF; Vogler WR
  • Evaluation of supportive care guidelines for monitoring breast cancer bone marrow transplant (BMT) patients in the outpatient setting.
    BLOOD Volume: 86 Page(s): 838 - 838
    11/15/1995 Authors: Miyahara TT; Dix SP; Devine SM; Holland HK; Connaghan DG; Fleming WH; Geller RB; Heffner LT; Hillyer CD; Waller EK
  • Tacrolimus (FK506) combined with methotrexate (MTX) is effective in preventing acute graft versus host disease (AGVHD) following related donor allogeneic bone marrow transplantation (BMT).
    BLOOD Volume: 86 Page(s): 1569 - 1569
    11/15/1995 Authors: Devine SM; Geller RB; Dix SP; Connaghan DG; Fleming WH; Heffner LT; Hillyer CD; Holland HK; Waller EK; Winton EF
  • Transplantation of HLA-identical positively selected CD34+ cells of peripheral blood (PBSC) and marrow (BM) from related donors results in prompt engraftment and low incidence of GVHD in recipients undergoing allogeneic transplantation
    BLOOD Volume: 86 Page(s): 1543 - 1543
    11/15/1995 Authors: Holland HK; Bray AM; Geller RB; Devine SM; McCollum J; Connaghan DG; Fleming WH; Heffner LT; Hillyer C; Waller EK
  • Risk factors for severe acute renal failure (ARF) after matched unrelated donor transplantation (MUDT).
    BLOOD Volume: 86 Page(s): 1552 - 1552
    11/15/1995 Authors: Redei S; Geller RB; Devine S; OToole K; Persons L; Holland HK; Connaghan G; Fleming WH; Heffner LT; Hillyer C
  • CRL-1336: First of a novel class of drugs used to reverse multidrug resistance (MDR1) gene expression in leukemia.
    Volume: 86 Page(s): 2069 - 2069
    11/15/1995 Authors: Shuster MW; Wei LX; Schulman P; Kolitz J; Buchbinder A; Allen S; Lichtman SM; Geller RB; Devine SM; Heffner LT
  • Pixy-321 in combination with high dose cytarabine end mitoxantrone in poor prognosis acute myeloid leukemia (AML).
    BLOOD Volume: 86 Page(s): 2068 - 2068
    11/15/1995 Authors: Feldman E; Geller RB; Seiter K; Heffner L; Stuart R; Bhalla K
  • SIMULTANEOUS ADMINISTRATION OF INTERLEUKEN-6 (RHIL-6) AND NEUPOGEN(R) (RHG-CSF) FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) FOR BREAST-CANCER (BCA)
    BLOOD Volume: 84 Page(s): A89 - A89
    11/15/1994 Authors: DEVINE SM; WINTON EF; HOLLAND HK; GELLER RB; HEFFNER LT; HILLYER CD; MORRIS LE; RODEY GE; BEVERIDGE R; LYNCH J
  • FK506-BASED IMMUNOSUPPRESSION FOR PREVENTION OF GRAFT-VERSUS-HOST-DISEASE (GVHD) AFTER MATCHED UNRELATED DONOR (MUD) MARROW TRANSPLANTATION
    BLOOD Volume: 84 Page(s): A341 - A341
    11/15/1994 Authors: DEVINE SM; GELLER RB; HOLLAND HK; MORRIS LE; WINTON EF; HEFFNER LT; HILLYER CD; RODEY GE; DIX SP; OTOOLE K
  • INTENSIVE TIME-SEQUENTIAL INDUCTION THERAPY WITH VP-16, MITOXANTRONE AND ARA-C FOR PATIENTS (PTS) WITH NEWLY-DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA (AML) OR REFRACTORY RELAPSE ACUTE-LEUKEMIA - A POTENTIAL ROLE FOR GM-CSF TO ENHANCE RECRUITMENT
    BLOOD Volume: 84 Page(s): A144 - A144
    11/15/1994 Authors: GELLER RB; MORRIS L; WINTON EF; BRAY R; HEFFNER LT; HOLLAND KH; GILMORE C; DEVINE S; FARHI D; JAMISON K
  • BONE-MARROW TRANSPLANTATION (BMT) FOR INDOLENT LYMPHOMA UTILIZING BUSULFAN (BU), CYCLOPHOSPHAMIDE (CY) AND ETOPOSIDE (E) FOLLOWED BY MAINTENANCE ALPHA-INTERFERON (IF) - 2-YEAR FOLLOW-UP RESULTS
    BLOOD Volume: 84 Page(s): A209 - A209
    11/15/1994 Authors: HOLLAND HK; HEFFNER LT; GELLER RB; DEVINE SM; HILLYER CD; WINTON EF; SARAL R; WINGARD JR
  • ASSOCIATION OF BUSULFAN AREA-UNDER-THE-CURVE (AUC) WITH VENOOCCLUSIVE DISEASE (VOD) FOLLOWING BONE-MARROW TRANSPLANTATION (BMT)
    BLOOD Volume: 82 Page(s): A418 - A418
    11/15/1993 Authors: DIX SP; MULLINS RE; JERKUNICA I; DAVIDSON TG; GILMORE CE; YORK RC; LIN LS; DEVINE SM; GELLER RB; HEFFNER LT
  • INTENSIVE TIMED SEQUENTIAL INDUCTION THERAPY WITH VP-16, MITOXANTRONE AND ARA-C FOR ADULT PATIENTS WITH ACUTE-LEUKEMIA
    BLOOD Volume: 82 Page(s): A538 - A538
    11/15/1993 Authors: GELLER RB; SIDHU GK; BRAY K; GILMORE C; KLEIN L; ROTHFIELD C; HEFFNER LT; HOLLAND HK; SEAY TE; WINTON EF
  • HIGH-DOSE BUSULFAN (BU), VP-16, CYTOXAN (CY) WITH MARROW RESCUE (BMT) FOR MULTIPLE-MYELOMA (MM)
    BLOOD Volume: 82 Page(s): A578 - A578
    11/15/1993 Authors: SEAY TE; DEVINE SM; GELLER RT; HEFFNER LT; HILLYER C; HOLLAND HK; RODEY GE; SARAL R; VOGLER WR; WINTON EF
  • Autologous bone marrow transplantation in acute leukemia with marrow purged with alkyl-lysophospholipid.
    Blood Volume: 80 Page(s): 1423 - 1429
    09/15/1992 Authors: Vogler WR; Berdel WE; Olson AC; Winton EF; Heffner LT; Gordon DS
  • Ophthalmological and other toxicities related to cytosine arabinoside and total body irradiation as preparative regimen for bone marrow transplantation.
    Bone Marrow Transplant Volume: 6 Page(s): 405 - 409
    12/01/1990 Authors: Vogler WR; Winton EF; Heffner LT; Gordon DS; Sternberg P; Crocker I; Reynolds R; Dobbs CK
  • Factors affecting survival in allogeneic bone marrow transplantation.
    Am J Med Sci Volume: 297 Page(s): 300 - 308
    05/01/1989 Authors: Vogler WR; Winton EF; Reynolds RC; Heffner LT; Gordon DS
  • FACTORS AFFECTING SURVIVAL IN ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT)
    EXPERIMENTAL HEMATOLOGY Volume: 16 Page(s): 495 - 495
    07/01/1988 Authors: VOGLER WR; WINTON EF; HEFFNER LT; GORDON DS; REYNOLDS RC
  • T-cell lymphoma following Hodgkin's disease.
    Cancer Volume: 56 Page(s): 1191 - 1196
    09/01/1985 Authors: Gowitt GT; Chan WC; Brynes RK; Heffner LT
  • Treatment of cutaneous T cell lymphoma with cyclosporin A.
    J Am Acad Dermatol Volume: 12 Page(s): 886 - 887
    05/01/1985 Authors: Moreland AA; Robertson DB; Heffner LT
  • TREATMENT OF CUTANEOUS T-CELL LYMPHOMA WITH CYCLOSPORIN-A
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Volume: 12 Page(s): 886 - 887
    01/01/1985 Authors: MORELAND AA; ROBERTSON DB; HEFFNER LT
  • Prolymphocytic leukemia of helper cell phenotype: report of a case and review of the scientific literature.
    Am J Clin Pathol Volume: 77 Page(s): 643 - 647
    05/01/1982 Authors: Chan WC; Check IJ; Heffner LT; Gordon D; Whitsett C; Brynes RK
  • CR-51 STUDIES VERIFY ANTI-PP1PK NOT DETECTABLE BY INVITRO CROSSMATCH AS CAUSE OF IMMEDIATE HEMOLYTIC TRANSFUSION REACTION
    TRANSFUSION Volume: 22 Page(s): 407 - 407
    01/01/1982 Authors: WHITSETT CF; DAFFIN LE; HEFFNER LT; SABO B; PIERCE JA
  • The detection of inferior vena caval thrombosis with computed tomography.
    Radiology Volume: 128 Page(s): 385 - 386
    08/01/1978 Authors: Steele JR; Sones PJ; Heffner LT
  • PHASE-1 STUDY OF 5FU - METHYL CCNU - METHOTREXATE WITH LEUCOVORIN IN ADVANCED ADENOCARCINOMA
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH Volume: 19 Page(s): 326 - 326
    01/01/1978 Authors: NIXON DW; VOGLER WR; JACOBS J; HEFFNER LT; WINTON EF; GARRETT PR
  • Transient peripheral plasmacytosis.
    Am J Clin Pathol Volume: 62 Page(s): 8 - 15
    07/01/1974 Authors: Moake JL; Landry PR; Oren ME; Sayer BL; Heffner LT
  • A study of Hansen's disease in Ceylon.
    South Med J Volume: 62 Page(s): 979 - 985
    08/01/1969 Authors: Heffner LT
Read more publications Fewer publications
Directory
  • Faculty Profiles
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2025 Emory University
  • Privacy Policy
  • Emergency Information
  • EEO Employer-Disability/Veteran Statements